Lexaria Bioscience (LEXX) Stock
Small biotech developing oral drug delivery platform. Here's the price, business snapshot, and what's worth knowing about Lexaria Bioscience in October 2026.
Lexaria Bioscience Corp (LEXX) is a small-cap biotechnology company developing DehydraTECH, a proprietary drug-delivery platform designed to improve the oral absorption and onset of active molecules such as cannabinoids, nicotine, vitamins and select pharmaceuticals. The company licenses its technology to partners and pursues clinical studies to validate performance claims. With a market capitalisation of about $20.15m, Lexaria remains an early-stage, development-focused business with limited commercial revenue and a modest balance sheet. Investors should weigh the potential of platform-enabled royalties and licensing revenue against clear risks: clinical or regulatory setbacks, slow partner uptake, financing needs and share-price volatility common to micro-cap biotechs. This summary is general, educational information only and not personal investment advice. Suitability depends on an individual’s risk tolerance, investment horizon and financial circumstances; consider seeking independent financial advice before investing. Past performance, if any, is not a reliable guide to future results and values can fall as well as rise.
Lexaria Bioscience (LEXX) Stock Forecast
Analyst price target, next 12 months
$52.50
+1722.9% vs today's $2.88
Price range over the last 12 months
Close to its 12-month low
Analysts covering Lexaria Bioscience have a consensus 12-month target of $52.50, above the current price of $2.88.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 15 Sep 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying Lexaria's stock, predicting it could reach $52.5 in value.
Financial Health
Lexaria Bioscience Corp is generating healthy revenue and cash flow, demonstrating strong financial management.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Delivery tech focus
DehydraTECH is the company’s core asset and explains investor interest; potential licensing revenue exists, though clinical and commercial success are not guaranteed.
Clinical progress matters
Trial results and regulatory updates can materially affect prospects; positive data may drive interest, while setbacks can hurt valuation.
Small‑cap volatility
With a market cap around $20m, Lexaria is a micro‑cap and may show large price swings and liquidity limits—suitability depends on risk tolerance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
